Orano Med’s ambition is to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells.
Despite considerable advances in oncology research in recent years, high unmet needs remain in a wide variety of cancer types.
Our approach, known as Targeted Alpha Therapy (TAT), has the potential to bring significant benefits where conventional therapies have failed to treat patients.
Member Number: 159
Member Since 2022, Company